Endocrine Abstracts

Background: Whether sitagliptin may affect oral cancer risk has not been investigated.

Methods: The reimbursement database of the National Health Insurance in Taiwan was used. Diabetic patients newly treated with sitagliptin (n=50033) or other antidiabetic drugs (n=277038) within 1999–2008 were followed for oral cancer until December 31, 2011. The treatment effect was estimated by Cox regression adjusted for propensity score (PS) or using PS weighting by inverse probability of treatment weighting approach.

Results: The overall hazard ratios suggested a 20% lower risk without statistical significance. In tertile analyses, the PS-adjusted hazard ratios for the first (<6.53 months), second (6.53–14.00 months) and third (>14 months) tertile of cumulative duration were 1.382 (0.899, 2.125), 0.908 (0.566, 1.456) and 0.464 (0.272, 0.789), respectively; and were 1.324 (0.864, 2.030), 0.871 (0.545, 1.394) and 0.447 (0.263, 0.760), respectively, for PS-weighted.

Conclusions: Sitagliptin may reduce oral cancer risk when the cumulative duration is >14 months.